UNSPSC 51284037: Oxytetracycline calcium

This classification denotes a tetracycline antibiotic with the molecular formula 2C22H23N2O9.CA, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier C8MRZ07FDV. European Medicines Agency schedules oxytetracycline calcium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03600MIG. The term oxytetracycline calcium is a U.S. Pharmacopeial Convention designation. Most nations, for tariff and trade purposes, schedule oxytetracycline calcium under HS 29413000 and SITC 54133.

UNSPSC 51284037 Oxytetracycline calcium, a Commodity code, shows minimal direct recent activity aligned with its nominal scope. The recent state and local opportunities tagged under this code involve pharmaceutical procurement broadly—naloxone kits, generic multi-source pharmaceuticals, and direct-to-manufacturer prescription programs—but do not specifically solicit oxytetracycline calcium or other tetracycline antibiotics. State and local governments use this code when acquiring injectable or oral tetracycline formulations for public health departments, correctional facilities, animal control programs, and emergency medical services, though the current solicitation record does not reflect active demand for this specific antibiotic at the state or local level. The issuing bodies posting under related pharmaceutical codes span state health agencies, county health departments, city fire departments, and multistate cooperative purchasing alliances; Minnesota's MMCAP alliance and Texas Health and Human Services Commission represent the largest current procurement vehicles for pharmaceutical products across multiple jurisdictions.

Geographic activity centers on Florida, Texas, and Minnesota based on recent postings. Seminole County, Florida issued an IFB (IFB60459723LAS) on June 30, 2026, for naloxone and drug deactivation systems with a due date of July 26, 2023, representing emergency medical supply procurement; the City of Tampa issued an ITB (26P00145) on March 25, 2026, for medical and first aid supplies with a $700,000 estimated value and a March 13, 2026, deadline, designated as a sheltered market opportunity for certified Small Local Business Enterprises. Texas HHS issued an RFI (HHS0017013) on April 3, 2026, to solicit vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program. Minnesota's MMCAP alliance posted an RFP (S1070000015802) on January 20, 2026, for generic multi-source pharmaceuticals and OTC products, with proposals due March 26, 2026, and effectiveness targeted for July 1, 2026. These opportunities reveal robust state and local demand for pharmaceutical supply chain solutions and emergency medical consumables, but oxytetracycline calcium itself shows no discrete recent solicitation.